Experts are growing increasingly concerned that there may not be a safe way for people to 'step down' from GLP-1 weight-loss medications, despite their rising popularity in helping combat obesity. Researchers have found that those who stop taking these medications often experience significant weight regain and a reversal of cardiovascular and metabolic health improvements.
A recent study published in JAMA Internal Medicine followed 670 participants with obesity or overweight who were treated with tirzepatide for 36 weeks, then randomly assigned either to continue the medication for another 52 weeks or receive a placebo. The results showed that among those who stopped taking tirzepatide, 82% regained at least 25% of their weight lost on the drug by week 88.
The study highlights the challenges of finding evidence-based ways for people to safely reduce or stop taking these medications. While some participants were able to maintain significant weight loss and metabolic improvements after stopping the medication, others experienced a complete reversal of their health benefits.
"This new class of drugs should be rebranded from 'weight loss' drugs to 'weight management' drugs," write medical experts at the University of Pittsburgh, highlighting the importance of recognizing these medications as long-term therapies for chronic diseases.
A recent study published in JAMA Internal Medicine followed 670 participants with obesity or overweight who were treated with tirzepatide for 36 weeks, then randomly assigned either to continue the medication for another 52 weeks or receive a placebo. The results showed that among those who stopped taking tirzepatide, 82% regained at least 25% of their weight lost on the drug by week 88.
The study highlights the challenges of finding evidence-based ways for people to safely reduce or stop taking these medications. While some participants were able to maintain significant weight loss and metabolic improvements after stopping the medication, others experienced a complete reversal of their health benefits.
"This new class of drugs should be rebranded from 'weight loss' drugs to 'weight management' drugs," write medical experts at the University of Pittsburgh, highlighting the importance of recognizing these medications as long-term therapies for chronic diseases.